Natera, Inc. (NTRA)
| Market Cap | 37.51B |
| Revenue (ttm) | 2.50B |
| Net Income (ttm) | -226.32M |
| Shares Out | 143.22M |
| EPS (ttm) | -1.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,411,831 |
| Open | 262.42 |
| Previous Close | 260.74 |
| Day's Range | 257.07 - 270.43 |
| 52-Week Range | 131.81 - 271.47 |
| Beta | 1.54 |
| Analysts | Buy |
| Price Target | 262.67 (+0.29%) |
| Earnings Date | Aug 6, 2026 |
About NTRA
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizo... [Read more]
Financial Performance
In 2025, Natera's revenue was $2.31 billion, an increase of 35.90% compared to the previous year's $1.70 billion. Losses were -$208.16 million, 9.31% more than in 2024.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for NTRA stock is "Buy." The 12-month stock price target is $262.67, which is an increase of 0.29% from the latest price.
News
Natera resumed with an Outperform at Bernstein
Bernstein analyst Eve Burstein resumed coverage of Natera (NTRA) with an Outperform rating and $310 price target following a return from maternity leave. “Many things” are going right for the…
Natera, Eledon announce strategic partnership
Natera (NTRA) and Eledon Pharmaceuticals (ELDN) announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of teg...
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage...
Natera price target raised to $275 from $270 at BTIG
BTIG raised the firm’s price target on Natera (NTRA) to $275 from $270 and keeps a Buy rating on the shares following news that Japan’s main regulatory body approved Signatera…
Natera announces Signatera receives regulatory approval in Japan
Natera (NTRA) announced that Signatera has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency, or PMDA. This approval supports the use of Signatera for patients with ...
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received regulatory approval from Japan's Pharm...
Natera price target lowered to $260 from $280 at Barclays
Barclays lowered the firm’s price target on Natera (NTRA) to $260 from $280 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and…
NCCN recommends ctDNA-MRD testing using Signatera technology
Earlier today, the company stated: “Natera (NTRA) announced that the National Comprehensive Cancer Network (NCCN(R)) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to incl...
Natera price target raised to $270 from $250 at BTIG
BTIG raised the firm’s price target on Natera (NTRA) to $270 from $250 and keeps a Buy rating on the shares. The company’s Signatera has jumped into NCCN guidelines, which…
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has update...
NCCN guidelines may be meaningful catalyst for Natera, says Leerink
Leerink analyst Puneet Souda tells investors in a research note that the latest NCCN bladder cancer guidelines newly support MRD testing in muscle-invasive bladder cancer and uniquely include Signater...
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced its robust scientific presence at the upcoming American Transplant...
Natera resumed with an Outperform at RBC Capital
RBC Capital resumed coverage of Natera (NTRA) with an Outperform rating and $275 price target The firm’s “constructive view” reflects Natera’s growth opportunities in minimal residual disease monitori...
Natera Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and an equity plan amendment, with all proposals approved by shareholders. No questions were raised, and final vote results will be published in a Form 8-K.
Natera Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Record Q1 performance led to raised revenue and margin guidance, with strong growth in Signatera and women's health. Robust clinical data and new product launches, including Fetal Focus and Latitude, support market leadership. Accelerated early cancer detection pipeline and international expansion signal long-term growth.
Natera initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Evie Koslosky initiated coverage of Natera (NTRA) with a Neutral rating and $245 price target The firm views Natera as the current leader in the molecular residual…
Natera, CytoDyn collaborate to advance ctDNA-guided development
Natera (NTRA) and CytoDyn Inc. (CYDY) announced a strategic collaboration to evaluate circulating tumor DNA dynamics and generate real-world molecular insights to support CytoDyn’s metastatic colorect...
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
AUSTIN, Texas & VANCOUVER, Wash.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stage on...
Natera appoints Lynch, Rubin to board of directors
Natera (NTRA) announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to the Company’s board of directors.
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to t...
Natera assumed with an Outperform at Wolfe Research
Wolfe Research analyst Paige Chamberlain assumed coverage of Natera (NTRA) with an Outperform rating and price target of $260, down from $275. As molecular residual disease “becomes more mainstream,” ...
CareDx denied request to Supreme Court to revive Natera award
A writ of certiorari was denied by the U.S. Supreme Court in the case of CareDx (CDNA) v. Natera (NTRA), meaning that the Court has declined to hear the appeal,…
Natera announces collaboration with Diakonos Oncology for Signatera in RM
Natera (NTRA) announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As part of the ...
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage...
Natera enrolls first patients in SIGNAL-ER 101 study
Natera (NTRA) announced enrollment of the first patients in SIgnatera-Guided iNterventionAL-ER 101, a prospective, single-arm, multi-center study evaluating Signatera MRD-guided de-escalation in early...